HS-10296 |
| カタログ番号GC39560 |
HS-10296 (HS-10296) は、EGFR 感作変異および T790M 耐性変異に対して高い選択性を持つ、経口投与可能な不可逆的な第 3 世代 EGFR チロシンキナーゼ阻害剤です。 HS-10296 は、T790M、T790M/L858R および T790M/Del19 に対して優れた阻害活性を示し (IC50: それぞれ 0.37、0.29 および 0.21 nM)、野生型に対してはあまり効果がありません (3.39 nM)。 HS-10296は非小細胞肺がんの研究に使用されています。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1899921-05-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
HS-10296, an orally available and third-generation EGFR-activating mutations and T790M-resistant mutation inhibitor, shows limited activity against wild-type EGFR[1][2].
[1]. Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76. [2]. Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018 Feb 19;17(1):38.
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *